Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Baxter Has Much Room for Growth in Japan: President Kawabata
February 25, 2008
- R&D NEWS IN BRIEF
February 25, 2008
- Korosho to Meet Concerned Parties to Improve Drug Distribution Practices
February 25, 2008
- OPINION／The Hottest Jobs in 2008 Revealed
February 25, 2008
- SSP to Promote Core Brand Strategy Based on 8 Products
February 25, 2008
- MEDICAL DEVICE NEWS IN BRIEF
February 25, 2008
- AZ Trains District Managers to Enhance Its Sales Forces
February 25, 2008
- Mediceo Paltac to Deal with Generics in Earnest
February 25, 2008
- Novartis to Launch Galvus in Europe
February 25, 2008
- Hansha Must Deal with Generics from All Companies: Mr Eguchi of Seibu Sawai
February 25, 2008
- FY2008 Revision of Medical Fees Recommended by Chuikyo
February 25, 2008
- Premium of 4 Points to Be Paid to Heavy Generic Dispensers
February 25, 2008
- BUSINESS NEWS IN BRIEF
February 25, 2008
- Generics to Be NHI Price Listed in May and November from FY2009
February 25, 2008
- NHI Pricing Procedures to See Changes
February 25, 2008
- TOPICS／Poster Prepared by Korosho to Promote Use of Generics
February 25, 2008
- JPA Satisfied with Proposed Dispensing Fees: JPA Vice President
February 25, 2008
- Piecework System Should Be Applied to Drugs Used at Nursing Care Facilities
February 25, 2008
- JPMA to Cooperate in Reduction in CO2 Emission
February 18, 2008
- Requirements for Self-injection of IFN, Etanercept Relaxed
February 18, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…